Business Context and Reporting Period
This Form 8-K Current Report was filed by SANUWAVE Health, Inc. on June 29, 2018, covering events occurring on June 14, 2018. The Company, a Nevada corporation, reported entering into a material definitive agreement with Johnfk Medical Inc. ("FKS") to establish a joint venture for the manufacture, sale, and distribution of its dermaPACE and orthoPACE devices.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The only specific financial figure disclosed relates to the new agreement:
- Initial Distribution Rights Fee (Taiwan): $500,000 paid by FKS on June 22, 2018.
- Future Distribution Rights Fee (SEA Region): $500,000 expected to be paid in the third quarter of 2018.
Material Changes
The primary material change is the execution of a joint venture agreement with FKS, effective June 14, 2018. This agreement expands the Company's distribution footprint into Taiwan and the Southeast Asia (SEA) region. The parties are scheduled to work toward a definitive agreement over the subsequent five months.
Guidance, Outlook, and Risks
Outlook: Management anticipates receiving an additional $500,000 fee in the third quarter of 2018 for distribution rights in the SEA region (Singapore, Malaysia, Brunei, Cambodia, Myanmar, Laos, Indonesia, Thailand, Philippines, and Vietnam). The Company is currently in a five-month window to finalize a definitive agreement with FKS.
Risks and Contingencies: The description of the agreement in this filing is not complete and is subject to the full text of the Agreement attached as Exhibit 10.1. The realization of future fees and the finalization of the joint venture depend on the execution of the definitive agreement.
Investor Verification Checklist
- Verify the full terms of the joint venture agreement in Exhibit 10.1 attached to the filing.
- Confirm the receipt of the initial $500,000 fee paid on June 22, 2018, in subsequent financial reports.
- Monitor the Company's progress toward finalizing the definitive agreement within the five-month window.
- Track the receipt of the second $500,000 fee scheduled for the third quarter of 2018.